Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling compa... by Lei Wang, Lulu Liu, Yiling Ding, Qilin Zhang, Yamin Shu

Get full text

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervica... by Yiling Ding, Chunping Wang, Yamin Shu, Jinglin Wang, Qilin Zhang

Get full text

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database by Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang

Get full text

Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024 by Yamin Shu, Wenxin Cheng, Xucheng He, Liu Huang, Wei Chen, Qilin Zhang

Get full text